Rockland Trust Co. Makes New Investment in Cencora, Inc. $COR

Rockland Trust Co. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 2,626 shares of the company’s stock, valued at approximately $821,000.

A number of other institutional investors and hedge funds have also made changes to their positions in COR. IFP Advisors Inc boosted its holdings in Cencora by 30.4% in the second quarter. IFP Advisors Inc now owns 1,775 shares of the company’s stock valued at $543,000 after acquiring an additional 414 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Cencora by 8.8% in the 2nd quarter. Blue Trust Inc. now owns 1,190 shares of the company’s stock worth $357,000 after purchasing an additional 96 shares during the period. Apollon Wealth Management LLC raised its holdings in shares of Cencora by 10.2% in the 2nd quarter. Apollon Wealth Management LLC now owns 6,556 shares of the company’s stock worth $1,966,000 after purchasing an additional 607 shares during the period. Concurrent Investment Advisors LLC lifted its stake in shares of Cencora by 8.9% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 9,421 shares of the company’s stock valued at $2,825,000 after purchasing an additional 767 shares in the last quarter. Finally, CWM LLC grew its holdings in shares of Cencora by 15.4% during the 2nd quarter. CWM LLC now owns 11,792 shares of the company’s stock worth $3,536,000 after purchasing an additional 1,575 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 20,316 shares of company stock valued at $7,151,265. Insiders own 0.38% of the company’s stock.

Cencora Trading Down 0.9%

NYSE COR opened at $360.00 on Wednesday. The company’s fifty day simple moving average is $346.17 and its 200-day simple moving average is $327.39. Cencora, Inc. has a 52 week low of $237.71 and a 52 week high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The stock has a market cap of $69.84 billion, a P/E ratio of 43.27, a PEG ratio of 1.67 and a beta of 0.68.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same period last year, the business earned $3.73 EPS. The business’s revenue was up 5.5% on a year-over-year basis. Equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be paid a $0.60 dividend. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is 28.85%.

Wall Street Analyst Weigh In

COR has been the subject of a number of research analyst reports. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. UBS Group increased their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Bank of America cut their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Wells Fargo & Company lifted their target price on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, TD Cowen upped their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $396.92.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: JPMorgan raised its price target to $419 and kept an “overweight” rating, implying roughly mid‑teens upside from current levels — a notable analyst endorsement that can support the stock. Benzinga
• Positive Sentiment: Cencora selected a new $106M distribution site in Greater Cincinnati (Hillwood), expanding logistics capacity that should support revenue growth and margin improvement over time. Cincinnati Business Journal
• Positive Sentiment: Pharma distribution wins: SQ Innovation’s Lasix ONYU gained access to major U.S. distributors, including Cencora, which could provide incremental product revenue and market‑access momentum. Yahoo Finance
• Neutral Sentiment: Cencora updated its segment reporting following a strategic business review; this improves disclosure but may temporarily complicate comparability to prior periods. TipRanks
• Neutral Sentiment: The company’s ~$2B physician‑group buyout is being framed as a strategic move into provider services; it supports growth strategy but carries integration risk and financing implications. Becker’s ASC
• Neutral Sentiment: Non‑financial/PR items such as executive recognition and analyst‑target aggregation pages surfaced; these are low impact on near‑term valuation. Yahoo Finance — Corporate Purpose
• Negative Sentiment: Cencora priced $3.0 billion of senior notes across five tranches (2029–2056) with coupons from 3.95% to 5.65% — a large debt raise that increases gross leverage and future interest expense; given the company’s already elevated debt metrics, the bond sale is the clearest near‑term headwind for the stock. Business Wire Yahoo Finance

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.